A recent meta-analysis demonstrated an improved response rate to ICB treatment among patients with HPV-positive HNSCC and a higher OS in patients with PDL1-positive HNSCC (Galvis et al.2020). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.